The authors reported that per-episode break-even prices for a resistance test vary sharply with ceftriaxone resistance levels. When ceftriaxone resistance was effectively absent, the per-episode cost-neutral price approached zero. Prices climbed as resistance rose; at a 15% prevalence of ceftriaxone resistance the threshold reached up to $48 per test. The team reported a scenario with 50% ciprofloxacin resistance and 5% ceftriaxone resistance where the population-weighted threshold was $7 for a ciprofloxacin-only test (95% uncertainty interval [UI] $3–$11) and $13 for a triple-target test (95% UI $8–$19). Short, direct summaries like these map test value to observable resistance prevalence—simple and actionable for payers and developers.
The study used an individual-level stochastic simulation of gonorrhea diagnosis and treatment tailored to the United States. Investigators built in empiric treatment pathways, diagnostic accuracy, symptom presentation, resistance distributions, partner management, and unit costs expressed in 2025 US dollars. They evaluated three testing strategies: a single-target ciprofloxacin assay, a two-target ciprofloxacin + ceftriaxone panel, and a triple-target panel that included a notional new drug (novel drug A). Multiple resistance scenarios were run to capture a wide range of possible futures.
The model produced three separate economic metrics. First, direct medical cost savings per clinical episode. Second, system-level costs attributable to emergence of ceftriaxone resistance among men who have sex with men (MSM). Third, avoided costs of developing a new antibiotic—used to estimate the maximum per-test price at which resistance-guided treatment (RGT) would remain cost-neutral. The authors made the simulation code and data publicly available on GitHub and archived outputs on Zenodo for reproducibility.
Per-episode savings were modest when ceftriaxone resistance was rare. The investigators found near-zero break-even prices in that setting, reflecting current US conditions. As resistance rose, immediate savings increased because tests directed oral therapy for susceptible infections (e.g., ciprofloxacin) and reduced use of the last-line intravenous agent ceftriaxone. The triple-target panel sometimes delivered lower per-test value in certain scenarios; that outcome reflected how broader testing increases the denominator of tests required to capture incremental benefit, diluting per-test returns when resistance remains uncommon.
When the authors shifted the perspective to MSM and included system-level costs tied to resistance emergence plus avoided antibiotic-development costs, the per-test value rose substantially. Depending on assumptions about prescribing behavior once ceftriaxone resistance reached 5%, the single-target test value among MSM ranged from about $31 to $114 per test; the triple-target test ranged from about $73 to $106 per test. These ranges reflect uncertainty in how clinicians and systems would respond to growing resistance and the large potential downstream costs that resistance imposes on treatment options.
The model rests on a set of explicit assumptions that materially affect outcomes. The primary assumption: resistance results are available during the same clinical visit and thus guide initial treatment. The authors reported that when treatment was given before test results returned, the modeled value fell by over 80%. The simulation did not represent onward transmission dynamics or co-resistance between antibiotics. It also counted only direct medical costs and did not attempt to quantify patient health outcomes or quality-of-life impacts. Longer-term value estimates were calculated only for MSM, limiting generalizability to other populations. The manuscript and appendices present deterministic sensitivity analyses; the code and data needed to reproduce those analyses are provided in the public repository.
Data indicated that resistance-guided therapy can justify nontrivial diagnostic prices under some plausible futures. Stakeholders—payers, diagnostic developers, and guideline committees—can use the three-tiered value framework reported here (immediate per-episode savings, system-level resistance costs, avoided antibiotic-development expenditure) when setting pricing and reimbursement strategies. The authors emphasized that how tests are deployed matters as much as what they detect; wider panels may require wider use to realize long-term benefits and therefore can have lower per-test economic returns in early-resistance settings.
The study ends with concrete limitations and open questions that should guide next steps. Key unresolved items include real-world turnaround times for resistance assays, the population-level impact of testing on transmission and co-resistance patterns (not modeled here), and how to translate system-level avoided costs into reimbursement pathways that incentivize deployment without encouraging unnecessary testing. The authors supply data and code to facilitate replication and further modeling that addresses these open questions.